About us
Our team
Experts in developing gene therapies for inherited retinal disorders
AAVantgarde Bio, based in Milan, is developing gene therapies for inherited retinal disorders. The founder, Professor Alberto Auricchio, is a highly recognized scientist and a pioneer in the field of gene therapy.
The company’s technology builds on existing AAV, or adeno-associated virus-based platforms, which are the main viral vector technology used in gene therapy applications. The company is a spin-off of TIGEM, an international research institute based in Naples that is owned and managed by the Telethon Foundation.
Our team
Natalia Misciattelli PhD
Chief Executive Officer
Prof. Alberto Auricchio
Founder and Chief Science Officer
Dr. Jayashree Sahni
FRCOphth, EMBA, MD
Nina Kotsopoulou PhD
Chief Technical Officer
Mike Murtagh
Senior Vice President Regulatory
Magda Blanco PhD, MBA
Head of Corporate Development
Board of directors
Natalia Misciattelli PhD
Chief Executive Officer
Mr. Mike Heffernan
Chairman
Paola Pozzi
Non-Executive Director (Sofinnova Telethon Fund)
Dr. Ram Palanki
Non-executive Director
Jason Rhodes
Non-Executive Director (Atlas Venture)
Dmitrij Hristodorov
Non-Executive Director (Forbion)
Dr. Lucy Liu
Non-executive director (Longwood fund)
Doug Kerr
Non-Executive Director (Dyne Therapeutics)
Peter Kaiser
Non-Executive Director